109 related articles for article (PubMed ID: 331908)
1. Membrane transport of antifolates as a critical determinant of drug cytotoxicity.
Goldman ID
Adv Exp Med Biol; 1977; 84():85-113. PubMed ID: 331908
[No Abstract] [Full Text] [Related]
2. Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate.
Hill BT; Bailey BD; White JC; Goldman ID
Cancer Res; 1979 Jul; 39(7 Pt 1):2440-6. PubMed ID: 221104
[No Abstract] [Full Text] [Related]
3. The cellular pharmacology of methotrexate.
Goldman ID; Matherly LH
Pharmacol Ther; 1985; 28(1):77-102. PubMed ID: 2414788
[No Abstract] [Full Text] [Related]
4. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.
Kuehl M; Brixner DI; Broom AD; Avery TL; Blakley RL
Cancer Res; 1988 Mar; 48(6):1481-8. PubMed ID: 2449950
[TBL] [Abstract][Full Text] [Related]
5. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
6. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts.
Rosowsky A; Lazarus H; Yuan GC; Beltz WR; Mangini L; Abelson HT; Modest EJ; Frei E
Biochem Pharmacol; 1980 Feb; 29(4):648-52. PubMed ID: 6929188
[No Abstract] [Full Text] [Related]
7. Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.
Sirotnak FM; Donsbach RC
Cancer Res; 1972 Oct; 32(10):2120-6. PubMed ID: 4404161
[No Abstract] [Full Text] [Related]
8. Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 Leukemia cells.
Sirotnak FM; Donsbach RC
Cancer Res; 1974 Feb; 34(2):371-7. PubMed ID: 4855750
[No Abstract] [Full Text] [Related]
9. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical aspects of folate transport].
Totskiĭ VN; Bondarchuk NG
Usp Sovrem Biol; 1979; 88(3):353-66. PubMed ID: 395787
[No Abstract] [Full Text] [Related]
11. Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Li WW; Lin JT; Schweitzer BI; Bertino JR
Mol Pharmacol; 1991 Nov; 40(5):854-8. PubMed ID: 1719370
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of dihydroaminopterin and the influence of aminopterin and related derivatives on the metabolism of (-)-5-formyl-tetrahydrofolic acid in Pediococcus cerevisiae.
Bühring KU; Fölsch E
Biochim Biophys Acta; 1976 Jan; 421(1):22-32. PubMed ID: 1247588
[TBL] [Abstract][Full Text] [Related]
13. The influence of folate antagonists on the metabolism of folic acid and its reduced derivatives in rat liver and kidney.
Bühring U; Shin YS; Fölsch E
Cancer Res; 1977 Jan; 37(1):299-304. PubMed ID: 830415
[TBL] [Abstract][Full Text] [Related]
14. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action.
Baggott JE; Morgan SL; Ha TS; Alarcón GS; Koopman WJ; Krumdieck CL
Clin Exp Rheumatol; 1993; 11 Suppl 8():S101-5. PubMed ID: 8324932
[TBL] [Abstract][Full Text] [Related]
15. Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF).
Pavlovic M; Leffert JJ; Russello O; Bunni MA; Beardsley GP; Priest DG; Pizzorno G
Adv Exp Med Biol; 1993; 338():775-8. PubMed ID: 8304227
[No Abstract] [Full Text] [Related]
16. Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates.
Matherly LH; Seither RL; Goldman ID
Pharmacol Ther; 1987; 35(1-2):27-56. PubMed ID: 2447596
[No Abstract] [Full Text] [Related]
17. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
18. Determinants of the disparate antitumor effects of (6R)5,10-dideaza-5,6,7,8- tetrahydrofolate and methotrexate toward methotrexate resistant CCRF-CEM cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM
Adv Exp Med Biol; 1993; 338():783-6. PubMed ID: 8304229
[No Abstract] [Full Text] [Related]
19. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
Sierra EE; Goldman ID
Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.
Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM
Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818
[No Abstract] [Full Text] [Related]
[Next] [New Search]
